Al­ler­gan’s Botox miss­es the bulls­eye in PhII de­pres­sion study, but re­searchers con­fi­dent they can hit it in a ma­jor PhI­II

Al­ler­gan’s siz­able Phase II study test­ing Botox as a treat­ment for ma­jor de­pres­sion among women missed hit­ting sta­tis­ti­cal sig­nif­i­cance for the pri­ma­ry end­point at six …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER